Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.65 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.65 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.65 |
| ▸ | ANPEP | P15144 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366407 | 0.90 | DPP4 (0.78) | DPP4NR1H2NR1H3ANPEPKMT2A | |
| SCHEMBL2820118 | 0.90 | DPP4 (0.78) | DPP4NR1H2NR1H3ANPEPKMT2A | |
| SCHEMBL10907340 | 0.84 | ANPEP (0.84) | DPP4NR1H2NR1H3ANPEP | |
| SCHEMBL11016604 | 0.84 | DPP4 (0.71) | DPP4NR1H2NR1H3ANPEP | |
| SCHEMBL10491139 | 0.84 | DPP4 (0.68) | DPP4NR1H2NR1H3ANPEPMEN1 | |
| SCHEMBL22334750 | 0.82 | DPP4 (0.53) | DPP4NR1H2NR1H3ANPEPMEN1 | |
| SCHEMBL11020887 | 0.82 | DPP4 (0.56) | DPP4NR1H2NR1H3ANPEP | |
| SCHEMBL11018434 | 0.81 | DPP4 (0.55) | DPP4NR1H2NR1H3ANPEP | |
| SCHEMBL11017462 | 0.81 | DPP4 (0.59) | DPP4NR1H2NR1H3ANPEP | |
| SCHEMBL11022208 | 0.81 | DPP4 (0.59) | DPP4NR1H2NR1H3ANPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11513132-B2 | Solid phase extraction, derivatization with crown ethers, and mass spectrometry, methods, reagents and kits | TECAN SP, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-11465404-B2 | On-press processing of a UV or violet-sensitized lithographic printing plate | AGFA OFFSET BV (BE) | 2022-10-11 | — | — | US | disclosed |
| US-11345766-B2 | Tetrahydro-as-indacenyl catalyst composition, catalyst system, and processes for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3452520-B1 | TETRAHYDRO-AS-INDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220032602-A1 | ON-PRESS PROCESSING OF A UV OR VIOLET-SENSITIZED LITHOGRAPHIC PRINTING PLATE | ECO3 BV (BE) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345766-B2 | Tetrahydro-as-indacenyl catalyst composition, catalyst system, and processes for use thereof | MLX, TXN, TSNAX | DPP4 3312/4885NR1H2 1266/4885NR1H3 1653/4885 |
| US-11513132-B2 | Solid phase extraction, derivatization with crown ethers, and mass spectrometry, methods, reagents and kits | CYP2C8, CES2, UGT1A8 | DPP4 114/4885NR1H2 583/4885NR1H3 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.